In March 18-19, 2023, the 8th Annual EBC Biotech Industry Conference took place at the Suzhou International Expo Center. During the event, the "2022 EBC Biotech Industry Annual Awards" winners were announced, with Hillgene Biopharma receiving the "2022 EBC Annual Top 100 Most Popular Product" award. As a leading platform for collaboration in the biotech industry, EBC has been hosting industry awards for seven consecutive years, and it is with great pleasure that we present the EBC Biotech Industry Annual Awards.

The award selection process was jointly assessed by the EBC organizing committee and a panel of experts, who evaluated the products based on multiple dimensions, including user recommendations, search exposure, order quantities, and total order value, among others. From a pool of 100 enterprises, 100 products were selected as award recipients.

Hillgene Biopharma was honored with the "2022 Most Popular Product Award." Over the past year, Hillgene, as a dedicated provider of cell therapy drug solutions, achieved significant milestones. The company obtained China's first production permit for a full-process CAR-T cell therapy drug, establishing itself as a trusted partner for cell therapy enterprises worldwide. Additionally, Hillgene Biopharma inked a major agreement with EncoreSail to initiate the CAR-NK CDMO project, jointly propelling the rapid development of intelligent NK cell therapy drugs in the coming year. Mr. Yongfeng Li, Hillgene's Chief Marketing Officer, accepted the award on behalf of the company.